Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-534

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 68001-534). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bortezomib 01)

Chemical structure of Bortezomib, the active ingredient shown in the image. The diagram depicts the molecule's detailed arrangement of atoms and bonds consistent with the lyophilized injection form of Bortezomib.*

FDA Label Image

Figure 1 (Bortezomib 02)

Kaplan-Meier survival curves comparing two patient groups over 26 months. The y-axis represents the percentage of patients, and the x-axis shows time in months. Two groups, labeled Vc-MP and MP, are shown with Vc-MP in red and MP in blue. Numbers of patients at risk for each time point are provided below the graph. A p-value from the log-rank test is noted at the bottom left of the graph.*

FDA Label Image

Figure 2 (Bortezomib 03)

A Kaplan-Meier survival curve comparing the percentage of patients over time (months) between two treatments labeled Vc-MP and MP. The graph includes a table showing the number of patients at risk for each treatment at various timepoints, and a p-value indicating statistical significance from a log-rank test is noted below.*

FDA Label Image

Figure 3 (Bortezomib 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time (in days) between two treatments: Bortezomib and Dexamethasone. The y-axis shows the proportion of patients, while the x-axis represents time in days up to 450 days. The graph includes patient counts at various time points and a p-value indicating statistical significance from a log-rank test.*

FDA Label Image

Figure 4 (Bortezomib 05)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) treated with Bortezomib versus Dexamethasone. The graph shows higher patient survival proportion for Bortezomib throughout the 450-day period. The x-axis represents time in days, and the y-axis represents the proportion of patients. Annotations include patient numbers remaining at specific time points and a p-value from a log-rank test indicating statistical significance (p<0.05).*

FDA Label Image

Figure 5 (Bortezomib 06)

A Kaplan-Meier survival curve chart depicting the percentage of patients over time (months) for two treatment groups labeled VcR-CAP and R-CHOP. The chart also includes a log rank test p-value of less than 0.001 and a table below showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 6 (Bortezomib 07)

A Kaplan-Meier survival curve chart depicting the percentage of subjects alive over time (months from randomization) comparing two treatment groups: VcR-CAP (solid line) and R-CHOP (dashed line). The chart includes a hazard ratio with 95% confidence interval and a table of subjects at risk for each group at various time points up to 108 months.*

FDA Label Image

Bortezomib Label (Image 01)

Bortezomib for Injection, 3.5 mg per vial, lyophilized powder for solution, labeled for intravenous or subcutaneous use. The single-dose vial label by BluePoint Laboratories includes dosage instructions, storage temperatures, manufacturer information (Kindos Pharmaceuticals Co., Ltd., China), and caution labeling as a cytotoxic agent. The label features NDC 68001-534-36 with barcode and lot/expiration date fields.*

FDA Label Image

Bortezomib Carton (Image 02)

Flat layout of Bortezomib for Injection 3.5 mg per vial cardboard carton. The label indicates it is a lyophilized powder for injection by intravenous or subcutaneous routes, with reconstitution instructions for both methods. The manufacturer is BluePoint Laboratories, with NDC 68001-534. The carton warns to discard unused portions and labels the drug as cytotoxic. It includes storage instructions and a barcode.*

FDA Label Image

Bortezomib Sticker (Image 03)

Bortezomib injection preparation instructions label showing two methods: Subcutaneous injection with 1.4 mL 0.9% Sodium Chloride to make 2.5 mg/mL final concentration, and Intravenous injection with 3.5 mL 0.9% Sodium Chloride to make 1 mg/mL final concentration. The label provides specific instructions to place corresponding stickers on vial and syringe. Labeler is BluePoint Laboratories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.